Copy Medical News Today
To get the approval, the company submitted safety and efficacy data from the DURATION clinical trial of Bydureon, backed by clinical experience with twice-daily injections of Byetta (exenatide).
Byetta is used in nearly 80 countries worldwide. It has been available in the US since June 2005.
Not to be reproduced without permission of Medical News Today
Main Category:Diabetes
Written by Catharine Paddock PhD
Bydureon uses Alkermes proprietary technology to provide controlled release of exenatide over the course of a week.
Please note thatwe publish your name, but wedo not publishyour email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see ourprivacy policyfor more information.
Dr John Buse is a professor of medicine, the director of the Diabetes Care Center, and chief of the Division of Endocrinology at the University of North Carolina School of Medicine in Chapel Hill. He said in a statement that with Bydureon, doctors and theidiabetes exerciser patients now have the option of a treatment that offers continuous control of blood sugar with just one dose per week:
The company describes Bydureon (exenatide extended-release for injectable suspension) as the first of its kind. It is a once-a-week version ofByetta, the companys 7-year-old diabetes drug that has to be injected twice a day.
1 (1 votes)
Please send any medical news or health news press releases to:
Article Date: 28 Jan 2012 - 15:00 PST
By the end of the study, both groups achieved statistically signficant weight loss, a secondary endpoint of the trial (average loss was 5.1 pounds, 2.3 kg, for those on Bydureon, and 3.0 pounds, 1.4 kg, for those on Byetta).
Also Included In:Regulatory Afirs / Drug Approvals
On Friday, the US Food and Drug Administration finally approved Amylin Pharmaceuticalsdiabetesdrug Bydureon, which provides glycemic control for diabetes type 2 in a once-weekly injection. The approval follows two earlier rejections in 2010, when the FDA asked the company to go back and carry out a new trial of the drugs effect on heart rhythm.
Other common side effects for the Bydureon group werediarrhea, upper respiratory tract infection and injection site nodules. There were no major hypoglycemic events, according to Amylin.
29 Jan. 2012. <
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read ourterms and conditions.
New treatment options are essential for the millions of adults with type 2 diabetes who continue to struggle to achieve optimal blood sugar control said Buse.
In the DURATION trial, Bydureon was tested head to head against Byetta for 24 weeks. The results showed that patients taking Bydureon experienced a a statistically superior reduction in A1C of 1.6 percentage points from baseline, compared to a reduction of 0.9 percentage points for those taking Byetta, said Amylin. (A1C is a measure of average blood sugar over three months.)
Get the latest news for this category delivered straight to your Twitter account. Simply visit ourDiabetes Twitter accountand select the follow option.
The drug, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for use alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. The company says it will be available in pharmacies throughout the US in February.
diabetes exercise Amylins Once-Weekly Diabetes Injection Finally Wins FDA Approval,
For any corrections of ctual information, or to contact the editors please use ourfeedback form.
More information:
All opinions are moderated before being included (to stop spam)
If you write about specific medications or operations, pleasedo notname health care professionals by name.
Contact Our News Editors
For FDA information on Bydureon go to theDrugs@FDA webpageand enter the name Bydureon into the search box.
View drug information onByetta.
The new drug has been approved with a Risk Evaluation and Mitigation Strategy (REMS) to make sure the benefits exceed the risk ocute pancreatitisand the potential risk of medullary thyroid carcinoma.
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.
Medical News Today. MediLexicon, Intl., 28 Jan. 2012. Web.
Diabetes (diabetes mellitus) is classed as a metabolism disorder. Metabolism refers to the way our bodies use digested food for energy and growth. Most of what we eat is broken down into glucose. Glucose is a form of sugar in the blood...Read more...
Full Boxed Warning and other safety information is available at the companys website for the drug
Amylin said it will also be fulfilling a number of post-marketing requirements to further assess the impact of BYDUREON on medullary thyroidcancerand cardiovascular disease.
The most common side effects in both groups was nausea, which was reported less frequently by the Bydureon users (14%) than the Byetta users (35%).
Based on postmarketing data, exenatide has been linked acute pancreatitis, including tal and non-tal hemorrhagic or necrotizingpancreatitis. And in animal studies, Bydureon caused rats to develop thyroid tumors, some of the cancerous.
